ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Editas Medicine (EDIT)
Editas Medicine stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$2.60▲ +8.33%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Editas Medicine in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Editas Medicine
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Editas Medicine a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $2.24 and $2.91; in 9 out of 10, between $1.77 and $3.68. Estimated annual volatility is 75%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $402M
- 52-week high
- $3.94
- 52-week low
- $1.66
- Revenue (12 months)
- $47.0M
- Revenue growth (YoY)
- +25.4%
- Gross margin
- 0.0%
- Operating margin
- -245.2%
- Net margin
- -395.0%
- Return on equity
- -118.8%
- Free cash flow (12 months)
- $-44.3M
- Beta
- 2.09
What this means
ATLAS does not publish a fair value for EDIT right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks EDIT has traded between $1.66 and $3.94. Today it is 34.0% below that high and 57% above its low.
On the business: revenue grew 25.4% year over year; net margin is 395.0%.
Its beta is 2.09: it tends to move more than the market, both up and down.
About the company
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions.
Want to see everything about Editas Medicine?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Editas Medicine do?
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genome editing medicines for serious diseases. The company’s work centers on CRISPR-based technologies, including Cas9 and Cas12a, which it uses to design precise therapies for genetically driven conditions.
What is the chance EDIT goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, EDIT ends the month between $2.24 and $2.91.
How big is Editas Medicine and what is its P/E ratio?
Editas Medicine's market capitalization is $402M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is EDIT?
ATLAS estimates annual volatility at 75%. In a typical month, half of the outcomes end between $2.24 and $2.91.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer